SCHEMBL6094657

SCHEMBL6094657

Cc1nc(Cl)c(N)c(Nc2ccc(C(C)CBr)cc2)n1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR1I2 O75469 1/20 0.36
AHR P35869 1/20 0.36
NFKB1 P19838 1/20 0.35
EGFR P00533 3/20 0.35
KDR P35968 3/20 0.35
KMT2A Q03164 4/20 0.34
ALDH1A1 P00352 2/20 0.34
MEN1 O00255 2/20 0.34
KDM4E B2RXH2 1/20 0.34
LMNA P02545 1/20 0.34
WDR5 P61964 1/20 0.34
FFAR2 O15552 1/20 0.34
TDP1 Q9NUW8 2/20 0.33
NPC1 O15118 2/20 0.33
RAB9A P51151 2/20 0.33
STK17B O94768 1/20 0.33
STK17A Q9UEE5 1/20 0.33
CYP1A2 P05177 1/20 0.33
CYP2D6 P10635 1/20 0.33
CYP2C9 P11712 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5236485 0.79 KDR (0.51) NR1I2AHREGFRKDRKMT2A
SCHEMBL13578943 0.74 NR4A1 (0.51) EGFRKDRKMT2AALDH1A1MEN1
SCHEMBL13578867 0.73 ROCK1 (0.47) EGFRKDRKMT2AALDH1A1MEN1
SCHEMBL17802551 0.72 KDR (0.46) EGFRKDRKMT2AALDH1A1MEN1
SCHEMBL6094653 0.71 WDR5 (0.40) KMT2AWDR5
SCHEMBL13578838 0.68 NPC1 (0.54) KMT2AMEN1LMNANPC1RAB9A
SCHEMBL13578882 0.68 EGFR (0.42) EGFRKDRKMT2AMEN1KDM4E
SCHEMBL11003633 0.66 KDR (0.50) NR1I2AHREGFRKDRKMT2A
SCHEMBL23547320 0.66 PDE10A (0.40) KMT2AMEN1LMNAWDR5TDP1
SCHEMBL29931161 0.66 PDE10A (0.40) KMT2AMEN1LMNAWDR5TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7074929-B2 Certain alkylene diamine-substituted heterocycles NEUROGEN CORP. (US) 2006-07-11 US disclosed
US-20040229870-A1 Certain alkylene diamine-substituted heterocycles NEUROGEN CORPORATION 2004-11-18 US disclosed
US-6696445-B2 NEUROPEPTIDE Y RECEPTOR ANTAGONISTS COMPRISING HETEROCYCLIC NITROGEN COMPOUNDS AND/OR PRODRUGS USED FOR PROPHYLAXIS OF EATING AND CARDIOVASCULAR DISORDERS NEUROGEN CORPORATION 2004-02-24 US disclosed
US-20030158197-A1 Certain alkylene diamine-substituted heterocycles NEUROGEN CORPORATION 2003-08-21 US disclosed
US-6506762-B1 Mono-, bi-, or tricyclic heterocycles may be modified to obtain potent antagonists at the NPY1 receptor. methods for the treatment of physiological disorders associated with an excess of neuropeptide Y. Novel compounds are for eating NEUROGEN CORPORATION 2003-01-14 US disclosed
EP-1224187-A2 CERTAIN ALKYLENE DIAMINE-SUBSTITUTED HETEROCYCLES NEUROGEN CORPORATION (US) 2002-07-24 EP disclosed
WO-2001023389-A2 CERTAIN ALKYLENE DIAMINE-SUBSTITUTED HETEROCYCLES NEUROGEN CORPORATION (US) 2001-04-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030158197-A1 Certain alkylene diamine-substituted heterocycles NPY1R, NPY5R, NPY2R NR1I2 278/4885AHR 501/4885NFKB1 3224/4885
US-20040229870-A1 Certain alkylene diamine-substituted heterocycles NPY1R, NPY5R, NPY2R NR1I2 303/4885AHR 511/4885NFKB1 3071/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.